Georgia Bio to Showcase State’s Leadership and Patients’ Perspectives in Bioscience Innovation at 2019 Innovation Summit

Atlanta, Georgia (September 26, 2019) – The Georgia Bio Innovation Summit is the southeast’s largest life science conference, showcasing Georgia’s leadership in innovation to improve the health and well-being of people, animals and the environment. This year’s Summit will bring together hundreds of CEOs, senior executives, scientists and public policy officials from Georgia and across the nation on October 8 at the Cobb Galleria in Atlanta.

How important is the life sciences industry to the state of Georgia? From 2007 to 2017, employment in life sciences grew by 14.9%, compared to 7.7% nationally, and 8.7% growth in private employment across all industries in the state.” An RTI report for Georgia Bio published earlier this year identified 1,960 unique life science establishments that contributed 68,300 jobs and $10 billion to Georgia’s Gross Domestic Product. Accounting for multiplier effects, the industry supports a total of approximately 194,000 jobs and contributes $21.8 billion to Georgia’s GDP.

The 2019 Breakfast Keynote is entitled ”Connecting Healthcare” from Dr. Jean-Christophe Tellier, UCB Global CEO. The Luncheon Keynote Address “Personalized Health in a Chaotic Environment” will be delivered by Marc Boutin, CEO of the National Health Council. 

“In order to innovate, first and foremost, we must connect the patient to the science,” Tellier told the Harvard Club of Belgium. “We are moving from treating the group of patients on one criteria [towards] a better understanding of patient subpopulations and trying to define much more precise solutions that better match their needs based on biologic signatures.”

Georgia Bio is putting special emphasis on the patient’s perspective into this year’s event. What does patient-centricity really mean in an industry that comprises 20 percent of the U.S. economy? We will hear from four local members of the International Children’s Advisory Network; young advocates for the importance of the patient’s voice in pediatric care. High school senior Ayana Ganesh, sophomore Ava Meisner, eighth grader Kalee Polk, junior Maci Yeager and moderator Leanne West who will share their first person accounts of what patient centricity and the importance of the patient voice means in pediatric care.

View the full program agenda here.

Did you know, according to AdvaMed, Fortune 500 companies with more than three women on the Board have 66% higher return on invested capital and a 42% higher return on sales?

Given those statistics, to ensure we hear directly from the voice of the patient, and to build awareness among aspiring young women for what is attainable in our industry, we have intentionally stacked our presenting faculty with women leading the state’s life science sector. Read more about the industry leading women in Georgia’s life sciences presenting. 

“We are entirely confident the 2019 edition of the Georgia Bio Innovation Summit will be of high value for any and all with an interest in Georgia’s life science community and driving better treatments and care to patients in Georgia and around the globe,” says Georgia Bio President and CEO Maria Thacker-Goethe.

Register here. 

About Georgia Bio

Georgia Bio is the state’s trade association committed to driving growth in Georgia’s biosciences industry and its many sectors, including agri-biotech, food and nutrition, bio-based technologies and renewable chemicals, industrial and environmental biotech, medical devices and technologies, pharmaceuticals and consumer healthcare, diagnostics and research products, testing and research services, and clinical research. Georgia Bio members include bioscience companies, academic and research institutions, bioscience service providers, digital health companies, and related organizations. For more information, visit www.gabio.org or follow us on Twitter @Georgia_Bio. 

Editor’s Note: Registration is complimentary for credentialed members of the news media. To request media registration, please contact Kristina Forbes at kforbes@gabio.org | 404-920-2043. 

Media Contact: 
Kristina Forbes
404-920-2043
kforbes@gabio.org

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.

GLS Joins Georgia Partners in Calling for Federal PBM Reform

December 7, 2025
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.
MORE POSTS